Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Inclusion Criteria: * Infants 55 to 75 days old, inclusive on the day of first vaccination * Born at full term of pregnancy (\> 37 weeks) * Informed consent form signed by the parent(s) or the legal guardian * Parents or the legal guardian able to read and write in the local language * Parent(s) or the legal guardian able to attend all scheduled visits and to comply with the study procedures. Exclusion Criteria: * Presence of fever (defined as rectal body temperature ≥ 38.0°C) reported within the last 72 hours * Moderate or severe acute illness with or without fever * Participation in another clinical trial in the 30 days preceding first study vaccination * Planned participation in another clinical trial during the present study period * Received diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b or a pneumococcal vaccine separately or in combination prior to study vaccination * Received any vaccination in the 30 days preceding the first study vaccination and/or is planning any vaccination within 6 weeks following any of the study vaccinations * Congenital or acquired humoral/cellular immunodeficiency or immunosuppressive therapy such as long-term systemic corticosteroids therapy (≥ 2 mg/kg/day prednisone equivalent for ≥ 14 days) in the previous 30 days * Systemic or local hypersensitivity to any of the study vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde) * History of life-threatening reaction(s) (such as encephalopathy, Hypotonic-Hyporesponsive Episode, rectal body temperature ≥ 40.0°C, convulsions with or without fever) to any vaccine containing the same components as the study vaccines * Blood or blood-derived products (immunoglobulins) received since birth * Known Human immunodeficiency virus (HIV) seropositivity * Known thrombocytopenia or other bleeding disorder contraindicating intramuscular vaccination * History of encephalopathy, seizures or progressive, evolving or unstable neurological condition * Clinically significant findings on review of systems that might interfere with study vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the study vaccine/objectives or pose a health risk to the subject.